Display options
Cite
Ragone C, Manolio C, Cavalluzzo B, et al. Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). J Immunother Cancer. 2021;9(5)doi: 10.1136/jitc-2021-002694.
Ragone, C., Manolio, C., Cavalluzzo, B., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., Castiglione, F., Vitagliano, L., Iaccarino, E., Ruvo, M., Tagliamonte, M., & Buonaguro, L. (2021). Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). Journal for immunotherapy of cancer, 9(5), . https://doi.org/10.1136/jitc-2021-002694
Ragone, Concetta, et al. "Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs)." Journal for immunotherapy of cancer vol. 9,5 (2021). doi: https://doi.org/10.1136/jitc-2021-002694
Ragone C, Manolio C, Cavalluzzo B, Mauriello A, Tornesello ML, Buonaguro FM, Castiglione F, Vitagliano L, Iaccarino E, Ruvo M, Tagliamonte M, Buonaguro L. Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002694. PMID: 34049932; PMCID: PMC8166618.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002694.

Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).

Journal for immunotherapy of cancer

Concetta Ragone, Carmen Manolio, Beatrice Cavalluzzo, Angela Mauriello, Maria Lina Tornesello, Franco M Buonaguro, Filippo Castiglione, Luigi Vitagliano, Emanuela Iaccarino, Menotti Ruvo, Maria Tagliamonte, Luigi Buonaguro

Affiliations

  1. Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"- IRCCS, Naples, Italy.
  2. Esperimental Oncology - Molecular Biology and Viral Oncogenesis, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"- IRCCS, Naples, Italy.
  3. Institute for Applied Computing, CNR, Roma, Italy.
  4. Institute for Biostructures and Bioimages, CNR, Roma, Italy.
  5. Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"- IRCCS, Naples, Italy [email protected] [email protected].

PMID: 34049932 PMCID: PMC8166618 DOI: 10.1136/jitc-2021-002694

Abstract

BACKGROUND: The host's immune system develops in equilibrium with both cellular self-antigens and non-self-antigens derived from microorganisms which enter the body during lifetime. In addition, during the years, a tumor may arise presenting to the immune system an additional pool of non-self-antigens, namely tumor antigens (tumor-associated antigens, TAAs; tumor-specific antigens, TSAs).

METHODS: In the present study, we looked for homology between published TAAs and non-self-viral-derived epitopes. Bioinformatics analyses and ex vivo immunological validations have been performed.

RESULTS: Surprisingly, several of such homologies have been found. Moreover, structural similarities between paired TAAs and viral peptides as well as comparable patterns of contact with HLA and T cell receptor (TCR) α and β chains have been observed. Therefore, the two classes of non-self-antigens (viral antigens and tumor antigens) may converge, eliciting cross-reacting CD8

CONCLUSIONS: An established antiviral T cell memory may turn out to be an anticancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the viral epitope. This may ultimately represent a relevant selective advantage for patients with cancer and may lead to a novel preventive anticancer vaccine strategy.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: CD8-positive T-lymphocytes; antigens; cellular; immunity; immunotherapy; vaccination

Conflict of interest statement

Competing interests: None declared.

References

  1. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7 - PubMed
  2. Oncoimmunology. 2014 Dec 02;3(12):e970914 - PubMed
  3. J Immunol. 2014 Mar 15;192(6):2885-91 - PubMed
  4. Proc Natl Acad Sci U S A. 1983 Apr;80(8):2346-50 - PubMed
  5. Cell. 1987 Sep 11;50(6):819-20 - PubMed
  6. J Transl Med. 2018 Oct 19;16(1):286 - PubMed
  7. Semin Immunopathol. 2019 Jan;41(1):69-85 - PubMed
  8. Expert Opin Biol Ther. 2003 Sep;3(6):985-93 - PubMed
  9. J Immunol. 1996 Sep 15;157(6):2539-48 - PubMed
  10. J Virol. 2009 Jan;83(1):304-13 - PubMed
  11. Immunology. 2009 Feb;126(2):165-76 - PubMed
  12. Prostate. 1989;15(1):13-21 - PubMed
  13. J Clin Invest. 2015 Sep;125(9):3401-12 - PubMed
  14. Cancer Res. 2003 Apr 1;63(7):1560-7 - PubMed
  15. Nat Rev Clin Oncol. 2014 Sep;11(9):509-24 - PubMed
  16. N Engl J Med. 2014 Dec 4;371(23):2189-2199 - PubMed
  17. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  18. Nat Rev Cancer. 2005 Aug;5(8):615-25 - PubMed
  19. J Mol Biol. 1996 Mar 1;256(3):623-44 - PubMed
  20. J Exp Med. 1997 Mar 3;185(5):833-41 - PubMed
  21. Vaccine. 2011 Jul 12;29(31):4903-12 - PubMed
  22. Int J Cancer. 2010 Jul 15;127(2):381-93 - PubMed
  23. BMC Bioinformatics. 2013 Apr 15;14:127 - PubMed
  24. J Clin Oncol. 2009 Oct 1;27(28):4685-92 - PubMed
  25. J Immunol. 2000 Jul 15;165(2):948-55 - PubMed
  26. Nature. 2017 Nov 23;551(7681):512-516 - PubMed
  27. Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454 - PubMed
  28. J Immunol. 2016 Aug 15;197(4):1517-24 - PubMed
  29. Clin Cancer Res. 2011 Feb 15;17(4):861-70 - PubMed
  30. Immunogenetics. 1994;39(2):121-9 - PubMed
  31. HIV Med. 2013 Sep;14(8):481-90 - PubMed
  32. Cell. 2014 May 22;157(5):1073-87 - PubMed
  33. Mol Ther. 2021 Jan 6;29(1):10-12 - PubMed
  34. J Natl Cancer Inst. 1997 Feb 19;89(4):293-300 - PubMed
  35. Oncoimmunology. 2016 Dec 7;6(2):e1252895 - PubMed
  36. Vaccines (Basel). 2020 Oct 17;8(4): - PubMed
  37. Oncotarget. 2016 May 3;7(18):25087-102 - PubMed
  38. Semin Oncol. 2015 Apr;42(2):247-57 - PubMed
  39. Expert Rev Vaccines. 2009 Oct;8(10):1379-98 - PubMed
  40. Immunity. 1999 Jun;10(6):673-9 - PubMed
  41. Immunol Res. 2011 Aug;50(2-3):261-8 - PubMed
  42. J Natl Cancer Inst. 2002 Jun 5;94(11):805-18 - PubMed
  43. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 - PubMed
  44. Science. 1985 Nov 29;230(4729):1043-5 - PubMed
  45. Genome Biol Evol. 2013;5(2):307-28 - PubMed
  46. PLoS One. 2010 Apr 16;5(4):e9862 - PubMed
  47. Oncoimmunology. 2015 Jan 9;4(4):e974411 - PubMed
  48. Cancer Res. 1998 Nov 1;58(21):4895-901 - PubMed

Publication Types